SEC Form 4 · accession 0001232524-15-000052

Jazz Pharmaceuticals plc · JAZZ

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, Finance & PAO

Period of report

Mar 3, 2015

Accepted (ET)

Mar 5, 2015 · 6:51 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001232524

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Ordinary Shares^F1	Mar 3, 2015	S	2,598	$176.27	D	21,046	D
Ordinary Shares	Mar 4, 2015	M	152	$46.83	A	21,198	D
Ordinary Shares	Mar 4, 2015	M	5,007	$27.46	A	26,205	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Incentive Stock Option (right to buy)^F2	$27.46	Mar 4, 2015	M	5,007	D	—	Mar 9, 2021	Ordinary Shares	5,007	0	D
Incentive Stock Option (right to buy)^F3	$46.83	Mar 4, 2015	M	152	D	—	Aug 8, 2022	Ordinary Shares	152	2,896	D

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.15 to $176.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2The ordinary shares subject to this option fully vested as of February 7, 2015.
F3This incentive stock option is part of an option granted on August 9, 2012 that consisted of this incentive stock option exercisable for 3,048 ordinary shares and a nonstatutory stock option exercisable for 26,952 ordinary shares. As of the date of this report, the remaining ordinary shares subject to this incentive stock option will vest with respect to 761 shares in equal monthly installments from March 9, 2015 to December 9, 2015 and with respect to 2,135 shares in equal monthly installments from January 9, 2016 to August 9, 2016.